Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

17.92 -0.64 (-3.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,859
Open 18.41
Bid (Size) 17.60 (1)
Ask (Size) 18.71 (1)
Prev. Close 18.56
Today's Range 17.68 - 18.41
52wk Range 10.68 - 21.28
Shares Outstanding 864,775,340
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
From HUTCHMED (China) Limited
Via GlobeNewswire
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

YTD
+9.40%
+9.40%
1 Month
-9.04%
-9.04%
3 Month
+20.67%
+20.67%
6 Month
+47.49%
+47.49%
1 Year
+30.71%
+30.71%

More News

Read More
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
Via Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
Via Investor's Business Daily
Rocket Pharmaceuticals Stock Sees Improved Price Strength
Via Investor's Business Daily
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
From Virtual Investor Conferences
Via GlobeNewswire
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Via Investor's Business Daily
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
Via Investor's Business Daily
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Via Investor's Business Daily
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Sarepta Therapeutics Stock Showing Rising Relative Strength
Via Investor's Business Daily
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Via Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
Via Investor's Business Daily
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.